Clinical Trials
5 trialsNCT02657486 2026-02-09
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT04228042 2025-01-01
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04972253 2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT01004224 2019-10-04
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Completed